These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 22114859

  • 1. Therapeutic potential of chemokine receptor antagonists for liver disease.
    Sahin H, Berres ML, Wasmuth HE.
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):503-13. PubMed ID: 22114859
    [Abstract] [Full Text] [Related]

  • 2. Chemokines as immune mediators of liver diseases related to the metabolic syndrome.
    Berres ML, Nellen A, Wasmuth HE.
    Dig Dis; 2010 Jul; 28(1):192-6. PubMed ID: 20460910
    [Abstract] [Full Text] [Related]

  • 3. Chemokines in liver inflammation and fibrosis.
    Wasmuth HE, Tacke F, Trautwein C.
    Semin Liver Dis; 2010 Aug; 30(3):215-25. PubMed ID: 20665374
    [Abstract] [Full Text] [Related]

  • 4. [Pathogenesis of liver fibrosis: modulation of stellate cells by chemokines].
    Wasmuth HE, Weiskirchen R.
    Z Gastroenterol; 2010 Jan; 48(1):38-45. PubMed ID: 20072995
    [Abstract] [Full Text] [Related]

  • 5. Chemokine-directed immune cell infiltration in acute and chronic liver disease.
    Karlmark KR, Wasmuth HE, Trautwein C, Tacke F.
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):233-42. PubMed ID: 19072358
    [Abstract] [Full Text] [Related]

  • 6. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics.
    Wald O, Weiss ID, Galun E, Peled A.
    Cytokine; 2007 Jul; 39(1):50-62. PubMed ID: 17629707
    [Abstract] [Full Text] [Related]

  • 7. CCR1 antagonists for the treatment of autoimmune diseases.
    Gladue RP, Zwillich SH, Clucas AT, Brown MF.
    Curr Opin Investig Drugs; 2004 May; 5(5):499-504. PubMed ID: 15202722
    [Abstract] [Full Text] [Related]

  • 8. Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis.
    Shahrara S, Amin MA, Woods JM, Haines GK, Koch AE.
    Arthritis Rheum; 2003 Dec; 48(12):3568-83. PubMed ID: 14674010
    [Abstract] [Full Text] [Related]

  • 9. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis.
    Tokuyama H, Ueha S, Kurachi M, Matsushima K, Moriyasu F, Blumberg RS, Kakimi K.
    Int Immunol; 2005 Aug; 17(8):1023-34. PubMed ID: 16000328
    [Abstract] [Full Text] [Related]

  • 10. CCR5 and CXCR3 are dispensable for liver infiltration, but CCR5 protects against virus-induced T-cell-mediated hepatic steatosis.
    Holst PJ, Orskov C, Qvortrup K, Christensen JP, Thomsen AR.
    J Virol; 2007 Sep; 81(18):10101-12. PubMed ID: 17626099
    [Abstract] [Full Text] [Related]

  • 11. The clinical potential of chemokine receptor antagonists.
    Ribeiro S, Horuk R.
    Pharmacol Ther; 2005 Jul; 107(1):44-58. PubMed ID: 15894378
    [Abstract] [Full Text] [Related]

  • 12. The chemokine family. Potential therapeutic targets from allergy to HIV infection.
    Proudfoot AE.
    Eur J Dermatol; 1998 Jul; 8(3):147-57. PubMed ID: 9649701
    [Abstract] [Full Text] [Related]

  • 13. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.
    Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH.
    J Immunol; 1999 Dec 01; 163(11):6236-43. PubMed ID: 10570316
    [Abstract] [Full Text] [Related]

  • 14. Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases.
    Elsner J, Escher SE, Forssmann U.
    Allergy; 2004 Dec 01; 59(12):1243-58. PubMed ID: 15507091
    [Abstract] [Full Text] [Related]

  • 15. Differential expression of chemokines and chemokine receptors in inflammatory periapical diseases.
    Silva TA, Garlet GP, Lara VS, Martins W, Silva JS, Cunha FQ.
    Oral Microbiol Immunol; 2005 Oct 01; 20(5):310-6. PubMed ID: 16101967
    [Abstract] [Full Text] [Related]

  • 16. Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection.
    Thomas LH, Friedland JS, Sharland M.
    Expert Rev Anti Infect Ther; 2007 Jun 01; 5(3):415-25. PubMed ID: 17547506
    [Abstract] [Full Text] [Related]

  • 17. Chemokine blockers--therapeutics in the making?
    Wells TN, Power CA, Shaw JP, Proudfoot AE.
    Trends Pharmacol Sci; 2006 Jan 01; 27(1):41-7. PubMed ID: 16310864
    [Abstract] [Full Text] [Related]

  • 18. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5.
    Pakianathan DR, Kuta EG, Artis DR, Skelton NJ, Hébert CA.
    Biochemistry; 1997 Aug 12; 36(32):9642-8. PubMed ID: 9289016
    [Abstract] [Full Text] [Related]

  • 19. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.
    Szczuciński A, Losy J.
    Acta Neurol Scand; 2007 Mar 12; 115(3):137-46. PubMed ID: 17295707
    [Abstract] [Full Text] [Related]

  • 20. High level expression, activation, and antagonism of CC chemokine receptors CCR2 and CCR3 in Chinese hamster ovary cells.
    Parody TR, Stone MJ.
    Cytokine; 2004 Jul 07; 27(1):38-46. PubMed ID: 15207250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.